- Shares of Halozyme (HALO) are up 7.5% before the open on modest volume as Citigroup initiates coverage on the stock with a Buy rating and $12 PT.
- On April 9 the FDA halted the company's PEGPH20 Phase 2 clinical trial while it investigates potential thromboembolic risks of the drug.
- Yesterday's close was $7.19.
From other sites
at 4-traders.com (Mon, 4:31PM)
at 4-traders.com (Mar 23, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs